Clinical Scorecard: Assessment of Urothelial Carcinoma Using Probe-Based Confocal Laser Endomicroscopy During Flexible Cystoscopy
At a Glance
Category
Detail
Condition
Urothelial carcinoma of the bladder (UCB), primarily non-muscle invasive bladder cancer (NMIBC)
Key Mechanisms
Probe-based confocal laser endomicroscopy (CLE) enables real-time optical imaging of bladder lesions during cystoscopy to assess cellular microarchitecture and differentiate benign from malignant lesions
Target Population
Patients with suspicious papillary bladder lesions planned for transurethral resection of bladder tumors (TURBT), excluding those with suspicion of carcinoma in situ only
Care Setting
Outpatient flexible cystoscopy and operative setting for TURBT
Key Highlights
Bladder cancer is the 10th most prevalent cancer worldwide, with urothelial carcinoma accounting for over 90% of cases in high-income countries.
High recurrence rates (up to 78%) in NMIBC necessitate frequent cystoscopic follow-up and contribute to patient burden and healthcare costs.
Probe-based CLE during flexible cystoscopy using the CystoflexF probe offers a feasible method for real-time in vivo histopathologic characterization of bladder lesions.
Guideline-Based Recommendations
Diagnosis
Use probe-based CLE during flexible cystoscopy with the CystoflexF probe to assess suspicious papillary bladder lesions in real time.
Perform histopathological analysis of resected tumor of interest (TOI) as the reference standard for diagnosis and grading.
Exclude patients with suspicion of carcinoma in situ only from CLE assessment.
Management
Instill fluorescein 0.1% into the bladder prior to CLE imaging to stain the extracellular matrix for enhanced visualization.
Use flexible cystoscopy with the CystoflexF probe for initial CLE imaging followed by rigid cystoscopy with the CystoflexUHD-R probe for comparative imaging.
Resect suspicious lesions according to standard clinical protocols following CLE imaging.
Monitoring & Follow-up
Conduct offline blinded assessment of CLE images by experienced observers after a wash-out period to evaluate diagnostic accuracy and interobserver variability.
Use combined grading with white light cystoscopy (WLC) images for exploratory clinical significance assessment.
Report diagnostic yield as the percentage of CLE recordings classified as diagnostic.
Risks
Exclude patients with fluorescein allergy or pregnancy from CLE procedures.
Recognize that CLE imaging with the CystoflexF probe has inferior imaging characteristics compared to the CystoflexUHD-R probe.
Patient & Prescribing Data
Patients undergoing evaluation for suspicious papillary bladder lesions with planned TURBT, excluding CIS suspicion
CLE imaging during flexible cystoscopy with the CystoflexF probe provides real-time diagnostic information that may reduce unnecessary repeat TURBTs and improve lesion characterization, potentially decreasing patient burden and healthcare costs.
Clinical Best Practices
Obtain informed consent and ensure adherence to institutional review board approvals and Good Clinical Practice guidelines.
Use a standardized protocol for fluorescein instillation and CLE imaging to ensure consistent image quality.
Perform blinded, independent image assessments with wash-out periods to minimize bias in diagnostic accuracy evaluation.
Combine CLE imaging findings with standard histopathology for definitive diagnosis and grading of urothelial carcinoma.
Consider the limitations of probe size and imaging resolution when selecting CLE probes for flexible versus rigid cystoscopy.
by Ben-Max de Ruiter, Jan Erik Freund, C. Dilara Savci-Heijnink, Jons W. van Hattum, Theo M. de Reijke, Joyce Baard, Guido M. Kamphuis, D. Martijn de Bruin, Jorg R. Oddens
